Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Genitourinary Cancers Symposium
Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real World Setting
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Preoperative Bone Metastases Not Prognostic in mRCC
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Neoadjuvant Immune-Chemotherapy Has Positive Effect in MIBC Cases
Combination neoadjuvant therapy with nivolumab and gemcitabine-cisplatin in patients with muscle-invasive bladder cancer resulted in significant pathologic downstaging at radical cystectomy, with manageable toxicities.
Risk Factors for Contralateral Testicular Tumors Identified
Treatment of a primary testicular germ cell tumor with chemotherapy reduces the risk of developing a contralateral testicular germ cell tumor, a study found.
Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium
